© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
October 25, 2022
Treatment with guselkumab resulted in greater improvements across key clinical and endoscopic/histologic outcome measures at week 12 compared with placebo in patients with moderately to severely active ulcerative colitis with or without a history of inadequate response or intolerance to advanced therapy.
The median DeMeester score decreased from 32-3.7 following LTF.
Patients with ulcerative colitis treated with combination induction therapy with guselkumab plus golimumab followed by guselkumab monotherapy achieved higher rates of the several end points at week 38 as compared to either guselkumab or golimumab alone.
Twelve additional weeks of subcutaneous risankizumab induction was efficacious and well-tolerated in patients with Crohn's disease following an initial risankizumab 12-week induction dose.
Risankizumab induction relieved Crohn's disease symptoms and maintenance doses were effective in resolving abdominal pain, with other mixed findings for other patient-reported outcomes in the maintenance phase.
If approved by the FDA, RBX2660 would be the first approved live microbiota therapeutic for the treatment of recurrent CDI.
The COVID-19 pandemic has hurt the effort of colorectal cancer screenings.
Treatment with terlipressin led to better long-term clinical outcomes for patients with hepatorenal syndrome who received a liver transplant.
October 24, 2022
On-demand vonoprazan at all investigated doses was significantly better than placebo in providing rapid and sustained relief from heartburn episodes in patients with nonerosive reflux disease.
Weekly dupilumab 300 mg versus placebo demonstrated statistically significant, clinically meaningful improvements in histologic and endoscopic outcomes and symptoms in adults and adolescents with eosinophilic esophagitis.
Paul Feuerstadt, MD: The Future of RBX2660
Fighting for Sight: Geographic Atrophy Drug Development Meets Its Future
Aflibercept Outperforms Bevacizumab at Weaning nAMD Patients Off Treatment